Review anchor
Phosphodiesterase 3B
SINGLE PROTEIN · Bos taurus
As of 2026-09-13
Evidence Snapshot
Phosphodiesterase 3B
CHEMBL5129
SINGLE PROTEIN
Bos taurus
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Phosphodiesterase 3B as ChEMBL target CHEMBL5129, mapped to UniProt E1BN64. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL5129
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
E1BN64
Phosphodiesterase
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Phosphodiesterase 3B matters
Phosphodiesterase 3B is reviewed as Phosphodiesterase (UniProt E1BN64); the current evidence base includes 4 approved drugs, 106 compounds, and 17 assays, with lead potency reaching pChEMBL 8.3.
Protein context
Phosphodiesterase
Phosphodiesterase Sequence length is 1115 aa.
Review this target as Phosphodiesterase 3B, mapped to UniProt E1BN64. ChEMBL maps the protein component as Phosphodiesterase. Sequence length is 1115 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt E1BN64
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 4 approved drugs, 106 compounds, and 17 assays for this target. The dominant activity type is IC50. CHEMBL103976 is the current potency anchor at pChEMBL 8.3.
Use CHEMBL103976 as the tractability anchor when discussing potency (pChEMBL 8.3).
Activity source · ChEMBL 36 via Core Engine
4 approved
pChEMBL 8.3
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Phosphodiesterase 3B matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt E1BN64, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
106
Total Compounds
17
Total Assays
4
Approved Drugs
IC50: 82.0, KI: 1.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL103976
|
8.3 | IC50 | — |
|
|
No preferred name
CHEMBL319217
|
7.3 | IC50 | — |
|
|
No preferred name
CHEMBL395336
|
7.0 | IC50 | — |
|
|
No preferred name
CHEMBL304389
|
6.0 | IC50 | — |
|
|
No preferred name
CHEMBL189
|
6.0 | IC50 | Approved |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
MILRINONE
CHEMBL189
|
1987 |
Source Header